LNAI

Lunai Bioworks Inc.

2.07 USD

Last updated Oct 7, 18:26 UTC

Yesterday HIGH

$1.2

Yesterday LOW

$1.13

52w HIGH

$13.28

52w LOW

$1.13

EPS

-0.80

PE

-2.59

Next Earnings

Oct 20, 2026

Overview News Government Trades Fundamentals

Lunai Bioworks Inc. stock is down -20.38% since 30 days ago. The next earnings date is Oct 20, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 44.44% of the previous 11 October’s closed higher than September.

Benzinga Insights

Tue Jun 16, 2026

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Newsdesk

Thu May 28, 2026

Lunai Bioworks' BioSymetrics And BrainStorm Therapeutics Announce Strategic Collaboration And LOI Integrating AI Discovery, Human Brain Organoid Modeling, And In Vivo Validation To Generate Differentiated Neurology Assets For Pharmaceutical Partnering And Development

Lunai Bioworks' (NASDAQ:LNAI) wholly owned subsidiary BioSymetrics and BrainStorm Therapeutics today announced a strategic collaboration and Letter of Intent (LOI) to jointly discover, validate, and advance novel
Benzinga Newsdesk

Fri May 22, 2026

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
Benzinga Newsdesk

Fri May 22, 2026

Federal Judge Granted Lunai Bioworks Permission On May 20 To Conduct Expedited Third-Party Discovery To Identify Naked Short Sellers Of Lunai Common Stock Through 2025-2026
Benzinga Newsdesk

Thu May 21, 2026

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
Benzinga Newsdesk

Wed May 20, 2026

Lunai Bioworks Announces 1-For-8 Reverse Stock Split Effective May 22
Benzinga Newsdesk

Fri May 15, 2026

Lunai Bioworks Inc. - Common Stock Q3 EPS $(0.10), Sales $20.942K

Lunai Bioworks Inc. - Common Stock (NASDAQ:LNAI) reported quarterly losses of $(0.10) per share. The company reported $20.942 thousand in sales this quarter.
Benzinga Newsdesk

Wed May 13, 2026

Lunai Bioworks Approves Reverse Stock Split At Ratio Of 1-For-3 To 1-For-30

Lunai Bioworks Inc. General Corporate Statement (Form8)Webmaster, Benzinga Editor UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to
Benzinga Newsdesk

Tue May 12, 2026

Lunai Bioworks Files Delaware Federal Lawsuit Against Naked Short-Sellers Who Traded ~554M Shares On March 17, 2026, Representing 15.3 Times Company's Total Outstanding Shares
Benzinga Insights

Tue May 5, 2026

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

CAT $811.64 USD

UUUU $10.29 USD

SMCI $44.66 USD

IWM $277.99 USD

ABBV $272.77 USD

CLSK $11.56 USD

DRAM DRAM $60.30 USD

IREN $38.45 USD